One-year KYSA-6 data showed KYV-101, a CD19 CAR T-cell therapy, produced durable, drug-free responses in generalized myasthenia gravis.
|Videos|May 30, 2020
CMSC 2020 Day 4: Jennifer Graves, MD, PhD, on the Role of Biological Aging in MS Progression
Author(s)NeurologyLive® Staff
Jennifer Graves, MD, PhD, presents her lecture titled, "The Role of Biological Aging in MS Progression" as part of the 2020 CMSC Virtual Annual Meeting.
Advertisement
For more coverage from CMSC 2020,
To register for the 2020 CMSC Virtual Annual Meeting, May 26-29, 2020,
To complete the evaluation and claim credit, go to
Advertisement
Related to this article
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 25, 2026.
MS Compass: Guiding Clinical Care, a podcast hosted by neuroimmunologist Lindsay Ross, MD, brings you an exclusive interview with Rachel Galioto, PhD. [LISTEN TIME: 33 minutes]
A. Blake Buletko, MD, and Galina Gheihman, MD, discuss their career paths in neurology, the role of mentorship and resilience, and strategies for navigating professional growth as early-career clinician-educators.
Final 15-month phase 1/2 data showed SKY-0515 improved cUHDRS scores and lowered mutant huntingtin protein in early-stage Huntington disease.
The FDA has granted Scholar Rock's apitegromab fast track designation for the treatment of patients with living facioscapulohumeral muscular dystrophy as the company's phase 2 FORGE study dosing begins.
Tonic motor activation therapy was associated with reductions in RLS severity, along with tolerable reductions in dopamine agonist dosing, in adults with medication-refractory RLS.
A migraine forecasting model achieved 91% precision using app data, but the study did not test whether next-day predictions improve care.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
SKY-0515 Shows Sustained Benefit at 15 Months in Huntington Disease
2
Ulefnersen Meets Primary End Point in Phase 3 FUSION Trial for FUS-ALS
3
Closing the Gaps in Cluster Headache Care: Jennifer Fokas, MD; Minali Nigam, MD
4
Xenon Submits New Drug Application for Azetukalner as Treatment for Focal Seizures
5